Jennifer Schranz, M.D.

Jennifer has over 24 years of experience in clinical development and medical affairs across small (Vicuron, Viropharma, Nabriva), mid-sized (Ipsen) and large pharmaceutical companies (Wyeth, Merck, GSK). Prior to this, Jennifer trained as a physician in internal medicine and infectious diseases, with a focus on HIV/AIDs, at the University of Toronto, Canada and SUNY Stonybrook, New York. During her career she has utilized traditional approaches to clinical development, as well as specialist approaches in rare and orphan diseases, working with small molecules, biologics and vaccines. Jennifer is Senior Vice President and Global Head of Rare Diseases at Ipsen and leads their strategy to advance rare disease therapeutics and transform the treatment of these often-neglected conditions. Ipsen’s rare disease portfolio currently focuses on bone and growth disorders (Fibrodysplasia Ossificans Progressiva, Severe insulin-like growth factor-1 deficiency) and rare liver diseases (Primary Biliary Cholangitis), with an additional interest in rare neuromuscular disorders. Jennifer is passionate about advancing research in rare disease to support underserved communities, whilst building high-performing teams to bring these medicines to patients in need.